VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight
Viking Therapeutics, Inc.
1,100 participants
Jun 23, 2025
INTERVENTIONAL
Conditions
Summary
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
Locations(134)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07104383